Local scientists 'develop' vaccine to prevent diarrhoea
Scientists in Bangladesh say they have developed a vaccine that will prevent diarrhoea, terming it a breakthrough in medical science. The vaccine, Dukoral, has been proven to thwart attacks of commonly found micro-organisms that cause diarrhoea. The term means a vaccine that acts against two types of bacteria. The scientists led by Dr David Sack of the International Centre for Diarrhoeal Disease, Bangladesh said Thursday that research since 1985 reveals that the vaccine shields the body against the bacteria for at least two years from its first dose.
bdnews24.com News Service
bdnews24.com
Published :
12 Apr 2007, 02:14 PM
Updated :
17 Aug 2022, 02:53 PM
Dhaka, Apr 12 (bdnews24.com) – Scientists in Bangladesh say they have developed a vaccine that will prevent diarrhoea, terming it a breakthrough in medical science.
The vaccine, Dukoral, has been proven to thwart attacks of commonly found micro-organisms that cause diarrhoea. The term means a vaccine that acts against two types of bacteria.
The scientists led by Dr David Sack of the International Centre for Diarrhoeal Disease, Bangladesh said Thursday that research since 1985 reveals that the vaccine shields the body against the bacteria for at least two years from its first dose.
In 1985 the scientists of the ICDDR,B began trials on the safety and efficacy of the vaccine in its Dhaka hospital, popularly known as cholera hospital.
The vaccine fights two most deadly and common bacteria:
Vibrio Cholerae
and
Escherichia Coli
.
The vaccine, to be taken in two doses 14 days apart, stops toxic agents released from attacking germs from entering cells in the intestine, averting diarrhoea trigger.
The two bacteria cause about 55 percent of all diarrhoea cases in Bangladesh, they said at a news briefing in the city's Bangladesh-China Friendship Conference Centre.
On average, about 55,000-60,000 children under five die from the two waterborne diseases a year.
Dr Firdousi Qadri, Dr Mohammad Yunus, Dr Abdus Salam and Dr David Sack carried out the successful trials in Bangladesh.
Now the vaccine is registered for sale in 50 countries.
This is the only cholera vaccine that is recommended by the WHO, and is licensed in over 20 countries. It has been tested in Asia, Africa and Latin America.
The availability of the oral vaccine may eventually save greater number of lives, especially of children who are more prone to the waterborne disease, researchers said.
Already approved by the World Health Organisation (WHO) and local Drug Administration, the vaccine is now popular among travellers, as it prevents even the most severe attacks of waterborne diseases.
Bangladesh is the only country in South Asia where the vaccine has been registered as a therapeutic product. For each country, drug registration takes four to five years. In many other countries, it is underway to get registered.
ICDDR,B executive director Dr David A Sack said: "I view launching of the vaccine as an important event since it is being introduced for the first time in Bangladesh."
"Although the price is high but I'm sure one day the vaccine would be reachable to the general population like the oral saline," Sack said.
The vaccine would be available only in authorized vaccination centres across the country, and one cycle or two doses would cost Tk 2,400 (Tk 1200 X 2).
The vaccine is manufactured at a pharmaceutical company -SBLVaccine in Sweden, and it must be preserved within 2-8 degrees Celsius temperature, according to the vaccine's profile.
"Considering the high price and benefits of the vaccine we would like to approach the government to include Dukoral in the national immunisation programme so that it can reach all classes of the people in Bangladesh," said Md Haliuzzaman, executive director of Healthcare Pharmaceuticals, the company that is licensed to distribute the vaccine here in the country.
bdnews24.com/nh/jr/ad/2001 hours